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Abstract 
Background: Oridonin (ORI) can inhibit proliferation and migration in various types of cancer cell lines. However, the 
exact mechanism remains unclear. We investigated the migration inhibitory effect of ORI on human pancreatic cancer 
SW1990 cells and dissected the possible molecular mechanism(s).
Methods: CCK‑8 assay was used to observe the cell viability. Wound healing assay, transwell assay and spontaneous 
metastasis model were used to observe the migration activities. Real‑time PCR, immunofluorescence, western blot 
analysis and immunohistochemistry methods were used to observe the expression of genes or proteins.
Results: ORI inhibited the migration of SW1990 cells. Real‑time PCR and immuno‑fluorescence analyses of epithelial‑
to‑mesenchymal transition (EMT) markers were compared between control group and ORI group. The expression 
of mesenchymal molecular markers, such as vimentin, snail and slug decreased. The expression of epithelial‑related 
marker E‑cadherin increased. Wnt/β‑catenin signalling was inhibited by ORI using luciferase reporter assay. ORI can 
decrease the β‑catenin protein level not only in the nucleus, but also in the cytoplasm and the whole cell after the 
treatment with ORI and glycogen synthase kinase 3β (GSK3β) was increased in the ORI‑treated group. CHIR could 
attenuate the effects of ORI in SW1990 cells. We established a mice model by injecting 1 × 106 SW1990 cells into 
nude mice intraperitoneally to test whether ORI affects tumour metastasis. Metastatic formation was inhibited by ORI 
(5 and 10 mg/kg) compared with the control group. Tumour sections stained with anti‑E‑cadherin, anti‑vimentin and 
anti‑β‑catenin antibodies revealed that ORI inhibited EMT, as well as the Wnt/β‑catenin pathway in vivo.
Conclusions: ORI can inhibit pancreatic cancer cell SW1990 migration and EMT by down‑regulating Wnt/β‑catenin 
signal transduction in vitro and in vivo. Therefore, it can be potentially and effectively used in the clinical management 
of pancreatic cancer.
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Background
Pancreatic cancer, which is one of the most common 
cancers of the digestive system, is a leading cause of 
morbidity and mortality in both developed and devel-
oping countries. Pancreatic cancer is characterised by a 
covert anatomical structure, aggressive biology, resist-
ance to conventional therapeutic agents, and no early 
detectable biomarkers were observed [1]. Consequently, 
pancreatic cancer presents a great challenge in oncol-
ogy, with a 5-year survival rate of only 5  % [2]. This is 
true for metastatic diseases, wherein the average life 
expectancy is just three to 6 months. Treatment options 
for pancreatic cancers are limited. Less than 20  % of 
patients with pancreatic cancer are subjected to surgi-
cal removal, whereas other patients are typically treated 
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with chemotherapy or chemotherapy with radiation. 
Pancreatic cancer is one of the few cancers in which 
survival has not improved substantially in 40  years. 
Therefore, searching for new strategies to prevent and 
treat pancreatic cancer is essential.
The epithelial-to-mesenchymal transition (EMT) is 
among the most critical processes that occur during the 
progression of tumour metastasis. EMT-induced adeno-
carcinoma cells can acquire malignant features, such as 
invasion, metastatic capabilities and chemo-resistance 
[3, 4]. In human pancreatic tumour samples, fibronectin 
and vimentin are increased in high-grade tumours, with a 
corresponding decrease in E-cadherin expression. These 
patients have worse prognoses than those who demon-
strate less evidence of EMT. Primary tumours with mes-
enchymal features (75 % of the total number of tumours) 
developed metastatic lesions to the liver and lungs [5]. 
Numerous signalling pathways that are involved in the 
regulation of EMT, such as transforming growth factor-
beta, notch and Wnt signalling pathways, are highly acti-
vated in metastatic pancreatic cancers and appear to be 
associated with prognosis [6–8].
Oridonin, a tetracycline diterpenoid compound 
extracted from the traditional Chinese medicine Rabdo-
sia rubescens, has anti-inflammatory, antibacterial and 
antitumour effects [9]. ORI inhibits the development of 
various types of cancers and is an effective and low-toxic 
antitumour medicine [10–12]. However, mechanisms 
underlying the antitumour activities of ORI, and whether 
or not it can suppress the migration of pancreatic cancer 
remain largely unknown.
We investigated the effects of ORI on pancreatic can-
cer cells. ORI inhibits pancreatic cancer cell migration 




ORI was purchased from the Yuanye Biological Insti-
tutions (Shanghai, China). Its purity was measured by 
HPLC and determined to be 99  %. ORI was dissolved 
in dimethyl sulfoxide (DMSO) to make a stock solution 
(10 mM) and stored at −20 °C. The DMSO concentration 
was kept below 0.1 % in all experiments and did not exert 
any detectable effect on cell growth or cell death. Fetal 
bovine serum (FBS), 0.25  % trypsin containing EDTA 
and high glucose DMEM were obtained from Gibco 
(USA). Cell Counting Kit-8 (CCK-8) was purchased from 
DoJinDo (Japan). RNA extraction kit was purchased 
from Life Technologies Co. CHIR99021, a GSK3β inhibi-
tor (R&D), was added into medium at a concentration of 
2 μM 1 h before administration of ORI.
Cell culture
Pancreatic cancer cell lines (Aspc1, Bxpc3, Panc1, 
SW1990) was obtained from the American Type Cul-
ture Collection (ATCC; Manassas, VA, USA). The cells 
were cultured in DMEM supplemented with 10  % FBS, 
100U/ml penicillin, and 100 μg/ml streptomycin at 37 °C 
in a humidified atmosphere of 5 % CO2, and subcultured 
when confluency reached 70–80 % by 0.25 % trypsin.
Cytotoxicity assay
The cytotoxic effect of ORI on pancreatic cancer cells 
was determined by using CCK-8 kit. Briefly, the loga-
rithmic phase cells were plated in 96-well culture plates 
(5  ×  103 cells per well). After 24  h of incubation, cells 
were treated with vehicle alone (0.1  % DMSO) or vari-
ous concentrations (7, 15, 31, 62, 125, 250  μM) of ORI, 
followed by a 48 h-culture. Each group had 6 wells, and 
CCK-8 (100  μl) was added to each well 1  h before the 
end of incubation. The absorbance at 450  nm was read 
using Bio-Tek, ELX800. Experiments were repeated three 
times. The cytotoxic effect was expressed as a relative 
percentage of cell death calculated as follows: Cell death 
(%)  =  100  −(dosing absorbance  −  blank absorbance)/
(control absorbance − blank absorbance) × 100.
Cell migration assay
A wound scratch assay was performed in order to study 
the migration of SW1990 cells. A 6-well plate was seeded 
with cells at 60  % confluence. After overnight incuba-
tion, a scratch was made at the centre of each well using 
a 200 μl pipette tip. Cells were further incubated with 0, 
7 or 15 μM ORI. Three parallel lines were drawn at the 
border of the wound, and the distance between the lines 
were measured 24  h post-scratching. The microscopic 
magnification (100×) of this area was photographed. The 
wound healing effect was determined by measuring the 
percentage of the migrating area compared with the area 
of the initial wound. Each experiment was conducted in 
triplicate.
Transwell migration assay
SW1990 cells were subjected to a transwell migration 
assay. 1  ×  105 cells were added to the upper chamber, 
and the lower chamber was filled with 7 or 15 μM ORI of 
culture medium containing no FBS. After incubation for 
24 h, cells in the upper chamber were carefully removed 
with a cotton swab, and cells that passed through the 
membrane to the lower chamber surface were fixed and 
stained with 0.5  % crystal violet. Cells from each well 
were counted in 3 random high-power fields under a 
microscope (100×). Each experiment was repeated in 
triplicate.
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Real‑time PCR
Total cellular RNA was extracted using TRIzol (Invitro-
gen) reagent. The reverse transcription was performed 
with 2 μg of total RNA, using an oligo (dT) primer and 
other reagents, and cDNA was synthesized using the 
Revert Aid First-Strand cDNA Synthesis kit (Thermo 
Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s protocol. Real-time PCR was carried out 
using the miScript SYBR Green PCR kit (Qiagen, Venlo, 
Netherlands). The cycle conditions for the PCR reaction 
were as follows: 95  °C for 15  min followed by 40 cycles 
of 60  °C for 20  s, and 72  °C for 40  s. The expression of 
each RNA was normalized to that of the internal control 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
The specific primer pairs used in this PCR reaction were: 
E-cadherin (NM_004360.3), forward: 5′-ACAGCCCC 
GCCTTATGATTCTC-3′, reverse: 5′-AAGCGATTGCC 
CCATTCG-TT-3′; vimentin (NM_003380.3), forward: 
5′-AGATGGCCCTTGACATTGAG-3′, reverse: 5′-CC 
AGAGGGAGTGAATCCAGA-3′; snail (NM_005985.3), 
forward: 5′-AATCGGAAGCCTAACTACAGCG-3′, 
reverse: 5′-GTCCCAGATGAGCATT-GGCA-3′; slug 
(NM_003068.4), forward: 5′-GTCCGCTCTGCCGCAC 
CTGA-3′, reverse:5′-GCTTGAGGGTCTGAATCTTG 
CT-3′; GAPDH (BC026907.1), forward: 5′-CTGCACC 
ACCAACTGCTTAG-3′, reverse: 5′-GTCTTCTGGGTG 
GCAGTGAT-3′. The changes of expression were calcu-
lated using the (2 [−ΔΔCT]) method. Each plate was run in 
triplicate.
Immunofluorescence
After treated with or without ORI, SW1990 grown on 
6-well plate were fixed in 4  % (w/v) paraformaldehyde 
and permeabilized with 0.1  % Triton-X 100 in PBS. 
E-cadherin (CST, 1:200), vimentin (CST, 1:200) and slug 
(CST, 1:200) were visualized by sequential incubation 
with indicated antibody overnight at 4 °C. Pictures were 
acquired by using a fluorescence microscope (Olympus).
Western blot
40 μg proteins were separated by 10 % sodium dodecyl 
sulfate–polyacrylamide gel (SDS-PAGE), and blotted 
onto polyvinylidene difluoride (PVDF) membranes. 
The membranes were incubated with the primary anti-
bodies against Histone H1 (Millipore, 1:1000), Non-
phospho (Active) β-catenin (CST, 1:1000), β-catenin 
(CST, 1:1000), GSK-3β(CST, 1:1000), GAPDH 
(KangChen Bio-tech, 1:1000) at 4  °C overnight sepa-
rately, and further incubated with horseradish peroxi-
dase (HRP)-conjugated secondary antibody (1:10,000; 
keyGEN-BIO) for 1 h. Bands were visualized by West-
ern Blotting Reagents (EMD Millipore, Billerica, MA, 
USA).
Luciferase reporter assay
Sub-confluent SW1990 cells were seeded in 24-well plate 
and transfected with 0.5  μg β-catenin/Tcf4 luciferase 
reporter (pTop-luc) per well with Lipofectamine (Invit-
rogen). After incubating for 12 h, cells were treated with 
0.1 % DMSO or 15 μM ORI. 24 h later, cells were lysed 
and subjected to luciferase assays using luciferase assay 
kit (Promega). Each assay was done in triplicate.
Spontaneous metastasis model and Hematoxylin & Eosin 
(H&E) staining
SW1990 cells (1 ×  106) in 50  μl PBS were injected into 
the nude mice intraperitoneally. Based on the different 
treatments, mice were segregated into 3 groups (each 
group has 5 mice). ORI (5  mg/kg and 10  mg/kg) was 
injected intraperitoneally every day for 10  days starting 
from the second day of SW1990 injection. Lungs were 
dissected and fixed in 10 % formaldehyde after 1 month. 
Paraffin-embedded lungs were cut for H & E staining.
Immunohistochemistry (IHC)
Immunohistochemistry analysis was performed on 5-mm 
sections of formalin-fixed paraffin-embedded lungs 
derived from mice. Serial sections were cut from each 
tissue, and further stained to evaluate the expression of 
EMT markers (E-cadherin and vimentin) and β-catenin 
(1:200).
Statistical analysis
Quantitative results were expressed as mean ± standard 
deviation (SD). The statistical analysis was performed by 
using two-tailed unpaired t test (between two groups) or 
one-way analysis of variance (ANOVA) (among three or 
more groups) under the computer software SAS 9.2 (SAS 
Institute Inc., Cary, NC, USA). A two-tailed P value <0.05 
was considered to be statistically significant.
Results
ORI inhibits cell migration in SW1990 pancreatic cell line
After treatment with different concentrations (7, 15, 31, 
62, 125 or 250  μM) of ORI for 12, 24, 36 and 48  h, the 
proliferation rates of four human pancreatic cancer cell 
lines (Axpc1, Bxpc3, Panc1, SW1990) were assessed via 
CCK-8 kit. As shown in Fig. 1a, ORI exhibited anti-pro-
liferative effects on all four cell lines in a concentration-
dependent manner, with SW1990 being the least sensitive 
to ORI. Therefore, we decided to use this cell line, which 
was derived from a spleen metastasis of a grade II pan-
creatic adenocarcinoma [13], to evaluate the role of ORI 
in pancreatic cancer metastasis and EMT.
IC50 of ORI in SW1990 of 24 h was 63.47 μM (Table 1). 
ORI at doses higher than 30  μM inhibited cell growth. 
ORI concentrations of 7 and 15  μM were used to treat 
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the cells for 24 h to evaluate the role of ORI in pancreatic 
cancer metastasis. The effect of ORI on cell migration 
was evaluated via wound healing and transwell migration 
assays. As shown in Fig. 1c and e, the migrative ability of 
SW1990 was significantly decreased after ORI treatment, 
compared with that in the control. Treatment with the 
15 μM ORI concentration resulted in 46 % reduction in 
cell migrative ability (Fig. 1c; P < 0.05).
EMT of SW1990 is affected by ORI
EMT is an early event in tumour migration. It is related 
to the structural changes in the intercellular junction, 
which is essential for migration [14]. We hypothesised 
whether the inhibition of tumour cell migration by ORI is 
associated with EMT. SW1990 were treated with 15 μM 
ORI for 24  h and evaluated for the expression of EMT 
markers by real-time PCR and immunofluorescent stain-
ing. Real-time PCR showed that the expression of mes-
enchymal markers, such as vimentin and transcription 
factors snail and slug, decreased, whereas the expres-
sion of epithelial-related genes E-cadherin was increased 
(Fig.  2a, b). However, immunofluorescent staining did 
not show significant changes of E-cadherin and slug.
ORI inhibits β‑catenin signalling in human pancreatic 
cancer cells
Given that stabilization and nucleus translocation of 
β-catenin are key events in transduction of the canoni-
cal Wnt/β-catenin signalling, which is highly involved 
in cancer metastasis, we conducted western blot analy-
sis to explore whether oridonin can suppress β-catenin 
activity. The results indicated that ORI can decrease 
the β-catenin protein level not only in the nucleus, 
Fig. 1 ORI inhibits SW1990 cell migration. a Cell viability was determined by using a CCK‑8 assay. b–e Cell migration was determined by using 
wound healing and transwell assay. The migrative ability of ORI group (7 and 15 μM) was compared with that in the control group. *P < 0.05, 
**P < 0.01, ***P < 0.001 vs. control group
Table 1 IC50 of ORI
IC50 (μM) 12 h 24 h 36 h 48 h
Axpc1 38.68 32.25 26.27 17.99
Bxpc3 65.41 37.51 29.30 21.66
Panc1 86.83 63.46 38.76 32.49
SW1990 87.25 63.47 38.95 32.57
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but also in the cytoplasm and the whole cell after the 
treatment with ORI for 24 h (Fig. 3b). Luciferase assays 
demonstrated that ORI dramatically suppressed the 
transcriptional activity of β-catenin (Fig. 3a). The sta-
bility of β-catenin in the cytoplasm is tightly regulated 
by the Axin/APC/GSK3β complex. Phosphorylation of 
β-catenin by GSK3β resulted in its degradation, which 
led to the inactivation of Wnt/β-catenin signalling 
[15–18].Thus, we investigated whether ORI could also 
affect the expression of GSK-3β, which is the negative 
regulator of Wnt/β-catenin signalling. As shown in 
Fig.  3b, the total expression level of GSK3β increased 
after ORI treatment. ORI may regulate Wnt/β-catenin 
signalling by enhancing the function of GSK3β in 
SW1990 cells.
CHIR attenuates the inhibitory function of ORI
To further validate the role of β-catenin and GSK3β 
in the migration inhibitory effect of ORI on SW1990 
cells, SW1990 was tested with CHIR, a GSK-3-specific 
inhibitor. CHIR attenuated the inhibitory function of 
ORI. WB results indicated that CHIR can reverse the 
decrease of the β-catenin in the cytoplasm, nucleus 
and the whole cell (Fig.  4d). As shown in Fig.  4a and 
b, after simulation with CHIR, the inhibited migration 
of SW1990 in the ORI group (15  μM) was markedly 
improved. Furthermore, the expression of E-cadherin 
decreased, whereas, the expression of vimentin, snail 
and slug increased after CHIR treatment (Fig.  4c, e, 
P < 0.05). These results suggest that down-regulation of 
β-catenin plays a critical role in the function of ORI in 
SW1990 cells.
ORI inhibits tumour metastasis in vivo
We injected 1  ×  106 SW1990 cells into nude mice to 
test whether ORI affects tumour metastasis. As shown 
in Fig.  5a, ORI treatment significantly decreased the 
body weight loss compared with the control. In addition, 
on the fourth week, two of the five mice in the control 
group died. By contrast, no death was recorded in the 
ORI group (5 and 10 mg/kg). Furthermore, lung metas-
tasis was significantly inhibited compared with the con-
trol group, even though no metastatic nodules could be 
observed by the naked eye. A representative lung from 
each group was shown in Fig. 5b. IHC analysis of tumour 
sections stained with anti-E-cadherin, anti-vimentin and 
anti-β-catenin antibodies revealed that ORI inhibited 
EMT as well as Wnt/β-catenin pathway in vivo (Fig. 5c).
Discussion
ORI is a tetracycline diterpenoid compound extracted 
from the traditional Chinese medicinal plant Rabdosia 
rubescens. It exerts immune protective effects in severe 
inflammatory diseases. ORI has shown remarkable anti-
proliferative and pro-apoptotic effects against leukemia 
and some types of solid tumours [19–23]. It also inhibits 
migration in various cancer cells [24–26]. ORI has been 
reported to significantly inhibit lung tumour metastasis 
through anti-angiogenesis by blocking Notch signalling; 
it also inhibits tumour invasion and metastasis in  vitro 
possibly by decreasing the expression of MMPs and regu-
lating the Integrin β1/FAK pathway in human breast can-
cer MDA-MB-231 cells. However, the effect of ORI on 
the migration of pancreatic cancer cells remains unclear. 
We investigated these mechanisms of ORI on pancreatic 
Fig. 2 Impact of ORI on EMT of tumor cells. a Real‑time PCR analysis of EMT markers were compared between control group and ORI group 
(15 μM). Data are presented as the mean ± SD, n = 3. b Immunofluorescence of EMT markers were compared between control group and ORI 
group (15 μM). *P < 0.05, **P < 0.01, ***P < 0.001 vs. control group
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cancer cells, and ORI can inhibit pancreatic cancer cell 
SW1990 migration and EMT by down-regulating Wnt/β-
catenin signal transduction.
EMT is defined by epithelial cells taking on a mesen-
chymal phenotype, characterised by loss of apical-basal 
polarity, increased cellular motility and reorganiza-
tion of cytoskeleton [27]. There are three major types of 
EMT: type 1 refers to embryogenesis; type 2 refers to 
wound healing; and type 3 refers to cancer and metas-
tases [28]. During the process of type 3 EMT, epithelial 
cells lose contact with their neighbours and gain mesen-
chymal properties, which enable them to break through 
the basement membrane for their metastatic dissemina-
tion. One of the hallmarks of EMT is the functional loss 
of E-cadherin (encoded by CDH1), which is thought 
to be a metastasis suppressor during tumour progres-
sion [29]. Vimentin and the transcription factors, snail 
and slug, are prominent inducers of EMT and strongly 
repress E-cadherin expression [30, 31]. Highly invasive 











NCa b 15μM ORI
Fig. 3 Functions of ORI relied on β‑catenin and GSK3β. a Luciferase assays. b Representative western blots for active β‑catenin, β‑catenin(total) and 
GSK3β levels in control or ORI group. Histone H1 and GAPDH were used as internal control. (N, nucleus; C, cytoplasm; W, whole cell)
Fig. 4 CHIR attenuated the inhibitory function of ORI. a and b Cell migration was determined by using wound healing and transwell assay. The 
migrative ability of CHIR group (2 μM CHIR + 15 μM ORI) was compared with that seen in the ORI group (15 μM). c Real‑time PCR analysis of EMT 
markers were compared between CHIR group(2 μM CHIR + 15 μM ORI) and ORI group (15 μM). d Representative western blots for active β‑catenin 
and β‑catenin(total) levels in ORI or CHIR group. Histone H1 and GAPDH were used as internal control. (N, nucleus; C, cytoplasm; W, whole cell).  
e Immunofluorescence of EMT markers were compared between CHIR group (2 μM CHIR + 15 μM ORI) and ORI group (15 μM). Data are presented 
as the mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. ORI group (15 μM)
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these cells displayed EMT characteristics and dramati-
cally enhanced invasive abilities with decreased levels of 
E-cadherin and increased vimentin, fibronectin, Twist 
and AKT2 [32]. Metastasis may be largely dependent on 
the ability of cancer cells to acquire EMT characteristics 
[33, 34]. Researchers found that paeoniflorin blocked the 
migration and invasion of breast cancer cells by repress-
ing EMT under hypoxic conditions [35]. Cui speculated 
that asparaginyl endopeptidase could promote the inva-
sion and metastasis of gastric cancer via EMT through 
AKT and MAPK signalling pathways [36]. Our results 
showed that the expression of mesenchymal molecular 
markers (vimentin, snail and slug) were decreased by 
ORI, whereas the expression of E-cadherin increased, 
indicating that ORI affects the EMT process in pancre-
atic cancer cells.
Wnt/β-catenin signalling pathway plays a critical role 
in various cancers [37, 38]. In the canonical Wnt/β-
catenin signalling, Wnt ligands bind to the dual receptor 
complex comprised of frizzled and low-density lipopro-
tein receptor-related protein 5/6 (LRP5/6). This leads to 
inactivation of the β-catenin destruction complex and 
Axin/APC/GSK-3β; the critical mediator β-catenin is 
relieved from its constitutive proteosomal degradation. 
β-catenin subsequently accumulates in the cytoplasm 
and translocates into the nucleus, where it associates 
with transcription factors to regulate the downstream 
target genes [39]. Increased cytoplasmic and/or nuclear 
accumulation of β-catenin protein is a common feature 
in human pancreatic cancers and it is involved in its 
pathogenesis [40]. The compounds from Chinese herbal 
medicine targeting Wnt/β-catenin signalling can be 
considered as suitable candidates for pancreatic cancer 
treatment. Given that ORI could activate GSK3β activ-
ity and up-regulate the expression of DKK1 in human 
osteosarcoma [41], the anti–migratory effect of ORI 
on pancreatic cancer cells might result from targeting 
Wnt/β–catenin signalling. Our data showed that ORI 
can reduce the protein levels of active β-catenin and its 
transcriptional activity in the nucleus. Moreover, inhib-
iting phosphorylation of GSK3β could attenuate the 
function of ORI on migration and EMT in SW1990. 
In addition, ORI-treated tumour xenografts express 
much lower levels of β-catenin compared with control 
tumours. It is then very likely that the effect of ORI on 
pancreatic cancer metastasis is due to its suppressive 
effect on β-catenin signalling.
Conclusions
Our data suggest that ORI can be effective for human 
pancreatic cancer. The anticancer effect of ORI in 
SW1990 cells may result from the suppression of EMT 
by increasing GSK-3β activity and inactivating Wnt/β-
catenin signal transduction. Future studies should be 
directed to the identification of more ORI target proteins, 
which are essential to elucidate the molecular mecha-
nisms underlying the anti-cancer capacity of ORI.
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Fig. 5 ORI inhibited tumor metastasis in vivo. a The change of body weight after injection of SW1990 and ORI. *P < 0.05, **P < 0.01, ***P < 0.001 vs 
control group. b Photographs of H&E staining of lung tissues from control or treatment (ORI) group were shown. c IHC images of lungs stained with 
E‑cadherin, vimentin and β‑catenin
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